Skip to content

LivaNova LIVN Neuromodulation — Foreign currency adjustments

Other segment segments

Cardiopulmonary
-$7.25M-161%

Similar metrics at other companies

Medtronic logo
MDTNeuroscience — Currency translation and other
$20M-81.1%
ROP
ROPNetwork Software — Currency translation adjustments
-$2.7M-151%
Gentex logo
GNTXOther — Foreign currency adjustment
-$52.83K
Stryker logo
SYKMedSurg and Neurotechnology — Foreign exchange and other
-$19M-204%
Lamb Weston logo
LWNorth America — Foreign currency translation adjustment
$24.1M+3,113%
Insight Enterprises logo
NSITNorth America — Foreign currency translation adjustment
$595.5K+161%

Other financials

Income statement

See full
Revenue$362.3M+14.3%
Gross profit$243.7M+12.7%
Operating income$41.5M-14.7%
Net income$22.3M+107%
EPS (diluted)$0.40+107%

Balance sheet

See full
Cash & equivalents$539.7M-26.9%
Total debt$340.9M-49.7%
Total equity$1.2B+17.1%
Total assets$2.5B-1.7%

Cash flow

See full
Operating cash flow$15.2M-36.5%
CapEx$14.3M+32.4%
Free cash flow$926.0K-93.0%

Valuation

See full
Market cap$4.32B+62.8%

Profitability

See full
Gross margin67.5%-0.5pp
Operating margin13.4%+0.8pp
Net margin-16.1%-18.0pp
FCF margin11.2%-0.2pp

Returns & leverage

See full
Return on equity-17.6%-19.5pp
Debt / equity0.3×-0.4×
Current ratio1.3×-0.2×

Where this comes from

Reported directly by LivaNova in its filing.

Tagged under the XBRL concept us-gaap:GoodwillTranslationAndPurchaseAccountingAdjustments.

The official record: LivaNova’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about LivaNova's neuromodulation — foreign currency adjustments.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is LivaNova's neuromodulation — foreign currency adjustments?
LivaNova (LIVN) reported neuromodulation — foreign currency adjustments of $0 in Q1 2026.
What does neuromodulation — foreign currency adjustments mean?
Reflects the impact of exchange rate fluctuations on the financial results of the Neuromodulation segment's international operations. This metric helps isolate operational performance from the volatility of global currency markets.